NYSE: CATX
Perspective Therapeutics, Inc.CIK 0000728387 · SIC 2834 · Pharmaceutical Preparations
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (HPQ 10-Q) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade CATX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Summary not yet generated.
Perspective Therapeutics files routine corporate presentation update
2 material changes detected. Sign up free to read the summary.
Perspective Therapeutics holds routine annual meeting, elects six directors for one-year terms
3 material changes detected. Sign up free to read the summary.
Perspective Therapeutics to present interim clinical trial results at ASCO 2026
2 material changes detected. Sign up free to read the summary.
net income -$26.2M. Perspective raises, extends cash runway to late 2027, advances three clinical programs
5 material changes detected. Sign up free to read the summary.
Perspective Therapeutics reports Q1 2026 financial results and business updates
2 material changes detected. Sign up free to read the summary.
Perspective Therapeutics discloses preliminary Q1 2026 cash position in analyst presentation
3 material changes detected. Sign up free to read the summary.
Perspective Therapeutics presents interim Phase 1/2a data for lead cancer drug VMT-α-NET
4 material changes detected. Sign up free to read the summary.
net income -$103.1M. Perspective advances VMT-α-NET to 6.0 mCi dose, raises, extends runway to late 2027
5 material changes detected. Sign up free to read the summary.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed Aug 10, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
(Dollars and shares in thousands, except for per-share amounts)
| Description | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Grant revenue | 81 | 290 | 157 | 632 |
| Operating expenses: | ||||
| Research and development | 21,544 | 16,620 | 42,916 | 30,952 |
| General and administrative | 7,795 | 7,709 | 14,780 | 15,551 |
| Total operating expenses | 29,339 | 24,329 | 57,696 | 46,503 |
| Operating loss | (29,258) | (24,039) | (57,539) | (45,871) |
| Non-operating income (expense): | ||||
| Interest income | 2,347 | 2,159 | 4,544 | 4,543 |
| Interest and other expense | (71) | (119) | (176) | (247) |
| Other income from a related party (Note 3) | - | - | - | 1,400 |
| Equity in loss of affiliate | (1) | - | (1) | (1) |
| Total non-operating income, net | 2,275 | 2,040 | 4,367 | 5,695 |
| Net loss from continuing operations | (26,983) | (21,999) | (53,172) | (40,176) |
| Net gain from discontinued operations | 197 | 514 | 197 | 514 |
| Net loss before deferred income tax benefit | (26,786) | (21,485) | (52,975) | (39,662) |
| Deferred income tax benefit | - | - | - | - |
| Net loss | (26,786) | (21,485) | (52,975) | (39,662) |
| Basic and diluted loss per share: | ||||
| Loss from continuing operations | (0.22) | (0.30) | (0.47) | (0.55) |
| Gain from discontinued operations | - | 0.01 | - | 0.01 |
| Basic and diluted loss per share | (0.22) | (0.29) | (0.47) | (0.54) |
| Weighted average number of shares used in computing net loss per share: | ||||
| Basic and diluted | 120,651 | 74,235 | 112,174 | 73,301 |
| Unrealized gain (loss) on available-for-sale securities | 5 | (16) | (331) | 54 |
| Comprehensive loss | (26,781) | (21,501) | (53,306) | (39,608) |
Condensed Consolidated Balance Sheets
(In thousands, except shares and par value data)
| Description | June 30, 2026 (unaudited) | December 31, 2025 |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | 48,488 | 30,629 |
| Short-term investments | 188,388 | 114,108 |
| Accounts receivable, net of allowance for doubtful accounts: $375 for each period | 269 | 6 |
| Prepaid expenses and other current assets | 4,378 | 3,646 |
| Total current assets | 241,523 | 148,389 |
| Noncurrent assets: | ||
| Property and equipment, net | 107,797 | 76,597 |
| Right-of-use asset | 2,196 | 1,500 |
| Intangible assets, in-process research and development | 40,000 | 40,000 |
| Other assets | 509 | 486 |
| Total assets | 392,025 | 266,972 |
| LIABILITIES AND STOCKHOLDERSʼ EQUITY | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | 29,418 | 20,511 |
| Lease liability | 1,097 | 623 |
| Accrued personnel expenses | 5,972 | 7,489 |
| Note payable | 57 | 56 |
| Total current liabilities | 36,544 | 28,679 |
| Noncurrent liabilities: | ||
| Lease liability, net of current portion | 1,269 | 1,005 |
| Note payable, net of current portion | 1,540 | 1,569 |
| Deferred Income (Note 3) | 26,600 | 26,600 |
| Deferred tax liability | 1,702 | 1,702 |
| Other noncurrent liabilities | 507 | 386 |
| Total liabilities | 68,162 | 59,941 |
| Commitments and contingencies (Note 10) | ||
| Stockholdersʼ equity: | ||
| Preferred stock: $0.001 par value; 7,000,000 shares authorized; 5,000,000 designated Series B convertible; no shares issued | - | - |
| Common stock: $0.001 par value; 750,000,000 shares authorized; 114,086,092 and 74,337,990 shares issued | 114 | 74 |
| Additional paid-in capital | 711,785 | 541,687 |
| Accumulated other comprehensive (loss) income | (221) | 110 |
| Accumulated deficit | (387,815) | (334,840) |
| Total stockholdersʼ equity | 323,863 | 207,031 |
| Total liabilities and stockholdersʼ equity | 392,025 | 266,972 |
Condensed Consolidated Statements of Cash Flows (Unaudited)
(In thousands)
| Description | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | (52,975) | (39,662) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Net accretion of discounts on available-for-sale securities | (1,151) | (1,765) |
| Depreciation and amortization expense | 2,267 | 1,465 |
| Share-based compensation | 5,599 | 4,501 |
| Other noncash income, net | 114 | 222 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (263) | (109) |
| Interest receivable | (250) | (286) |
| Prepaid expenses and other current assets | (482) | 259 |
| Accounts payable and accrued expenses | (3,581) | (4,548) |
| Deferred Income1 | - | (1,400) |
| Accrued personnel expenses | (1,517) | (441) |
| Other noncurrent liabilities | 121 | 229 |
| Net cash used in operating activities | (52,118) | (41,535) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Additions to property and equipment | (21,053) | (5,682) |
| Additions to other assets | (21) | (45) |
| Purchases of available-for-sale securities | (185,952) | (67,094) |
| Maturities of available-for-sale securities | 112,492 | 71,520 |
| Net cash used in investing activities | (94,534) | (1,301) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Repayment of note payable | (28) | (26) |
| Proceeds from sales of common stock pursuant to exercise of options | 450 | 145 |
| Proceeds from the sale of common stock pursuant to at-the-market offering, net1 | - | 9,986 |
| Proceeds from issuance of common stock and Pre-funded Warrants, net1 | 164,089 | - |
| Net cash provided by financing activities | 164,511 | 10,105 |
| Net increase (decrease) in cash and cash equivalents | 17,859 | (32,731) |
| Cash and cash equivalents at beginning of period | 30,629 | 61,580 |
| CASH AND CASH EQUIVALENTS AT END OF PERIOD | 48,488 | 28,849 |
| Supplemental schedule of noncash investing and financing activities: | ||
| Additions to property and equipment in accounts payable and accrued expenses | 12,411 | 1,058 |
| Recognition of operating lease liability and right-of-use asset | 1,250 | - |
Amounts as printed on the EDGAR/iXBRL face — (Dollars and shares in thousands, except for per-share amounts); (In thousands, except shares and par value data); (In thousands). Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗